Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05641324
Other study ID # ANV419-102
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date February 10, 2023
Est. completion date July 12, 2023

Study information

Verified date February 2024
Source Anaveon AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.


Description:

The purpose of this multi-site, open-label, Phase 1 adaptive design study is to evaluate the safety, tolerability and preliminary efficacy of ANV419 as a monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab in patients aged 18 years or older with with relapsed or refractory Multiple Myeloma.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date July 12, 2023
Est. primary completion date July 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Must provide written informed consent for the study; - Must be able to comply with the Protocol as judged by the Investigator; - Are =18 years of age on the day of signing informed consent - Have been diagnosed with symptomatic MM per CRAB (calcium elevation, renal dysfunction, anemia, bone disease) criteria; - Have had evidence of a response (defined as partial response [PR] or better according to IMWG response criteria [Appendix C]) during previous treatment; - Have undergone treatment with ASCT or have progressed from at least 2 other prior treatment lines (including an immunomodulatory imide drug and/or daratumumab); - Have relapsed on, or been refractory or intolerant to, the last treatment line, and have measurable disease evaluated by monoclonal proteins (M-proteins) and/or free light chains according to IMWG response criteria (Appendix C). Non-secretory MM must have measurable, active lesions by positron emission tomography; - Have a performance status of 0 to 2 on the ECOG Performance Status; - Have adequate organ functions; - Willing to undergo bone marrow biopsies if determined clinically feasible based on the Investigator's assessment; - Are eligible for treatment with daratumumab; - Are eligible for treatment or re-treatment with lenalidomide (as per the European Medicines Agency labeling criteria); - Are eligible for prophylaxis for thromboembolism per IMWG response criteria; - Female patients of childbearing potential must have a negative serum pregnancy test at screening and a negative (urine or serum) pregnancy test within 72 hours prior to receiving the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required and must be negative for the patient to be eligible; - Female patients who are not postmenopausal, and who have not undergone surgical sterilization, must agree to use highly effective methods of contraception during the treatment period and for 6 months after the last dose of study drug. They must also agree not to donate eggs (ova, oocytes) during the same timeframe; and - Male patients with partners of childbearing potential must agree to use highly effective methods of contraception and barrier contraception (condom) during the treatment period and for 6 months after the last dose of study drug. They must also agree not to donate sperm during the same timeframe. Exclusion Criteria: - Have received an investigational agent (including investigational device) <4 weeks or 5 half-lives prior to study Cycle 1 Day 1, whichever is longer; - Have hypersensitivity to any components of ANV419 (IL-2, anti-IL-2 mAb) or its formulation (L-histidine, L-histidine HCl, sucrose, polysorbate 80, water; see Appendix D); - Have hypersensitivity to lenalidomide, dexamethasone, daratumumab, or any of their excipients; - Have received daratumumab <3 months prior to the signing of informed consent; - Have received any drugs that may be active for MM <3 weeks prior to the signing of informed consent; - Have received high-dose corticosteroids (=1 mg/kg) =3 weeks prior to the signing of informed consent; - Have received radiotherapy =1 month prior to the signing of informed consent; - Have had an autologous hematopoietic cell transplant (HCT) within the last 6 months; - Have had a previous allogeneic HCT; - Have had major surgery <4 weeks prior to the signing of informed consent or anticipate the need for major surgery during treatment; Note: Major surgery is defined as any surgery requiring entrance into a body cavity (eg, chest, abdomen, or brain), organ removal, normal anatomy alteration, or joint replacement. Minor surgery is defined as any surgery in which skin, mucosa, or connective tissue sections are altered (eg, biopsy, cataract, endoscopic procedures, etc). - Have clinical signs of meningeal involvement of MM; - Have a history of a past or current malignancy prior to screening, except for: 1. Cervical carcinoma of Stage 1B or less; 2. Non-invasive basal cell or squamous cell skin carcinoma requiring treatment; or 3. Current or past malignancy with a complete response for <3 years at screening. - Have plasma cell leukemia defined as a plasma cell count >2000/mm3; - Have known amyloidosis; - Have sensory and/or motor neuropathy =Grade 3 per NCI CTCAE version 5.0 at screening; - Have active (measurable) and/or uncontrolled (unresponsive to current therapy) infectious disease (bacterial, fungal, viral, or protozoic); - Have evidence of uncontrolled (unresponsive to current therapy), concomitant disease including, but not limited to, uncontrolled diabetes mellitus (pre-existing diabetes mellitus type 1 is acceptable), chronic obstructive pulmonary diseases Grade 3 (per NCI CTCAE version 5.0) or higher, asthma, bronchospasm, obstructive pulmonary disease, hematological diseases except MM, renal impairment (except when related to MM), hyperthyroidism due to thyroiditis, known autoimmune disease, or disease with ongoing fibrosis; - Have clinically significant (defined as a disease that requires intervention) cardiovascular disease including, but not limited to, acute myocardial infarction and/or transient ischemic attack <6 months prior to screening, unstable angina, congestive heart failure (New York Heart Association Class II or higher), or arrhythmia requiring therapy; - Have an average QTcF interval >480 msec at screening; - Have active, untreated, immune-related endocrinopathy untreatable with hormone replacement or prior immune-related toxicities (eg, colitis, neuropathy) >Grade 3 (per NCI CTCAE version 5.0) after treatment with immunostimulatory drugs that have not been resolved; - Have evidence of severe hepatic impairment (equivalent to Child-Pugh Class C [for liver cirrhosis] or a MELD [Model for End-Stage Liver Disease] score of 10 or higher for hepatic impairment not limited to cirrhosis]); - Have a history or current evidence of any condition, therapy, or laboratory abnormality that might significantly confound the results of the study, interfere with the patient's participation for the full duration of the study, or it is not in the best interest of the patient to participate in the study, in the opinion of the treating Investigator; - Have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study; - Are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, from screening through 6 months after the last dose of study drug; - Are known to be human immunodeficiency virus (HIV) positive (or tests positive for HIV 1 or 2 at screening), unless the following criteria are met: 1. CD4+ lymphocyte count >350 µL; 2. Had no history of AIDS (acquired immunodeficiency syndrome)-defining opportunistic infections within the past 12 months; 3. Have been on established anti-retroviral therapy for at least 4 weeks; and 4. Have an HIV viral load of <400 copies/mL prior to study Day 1. Note: Patients on strong cytochrome P450 (CYP)3A4 inhibitors or strong CYP3A4 inducers must be switched to an alternate effective anti-retroviral therapy regimen prior to study treatment or are excluded if regimen prior to study Day 1 cannot be altered. - Have uncontrolled hepatitis B infection or hepatitis C infection; Note: Patients with hepatitis B (positive hepatitis B surface antigen) who have controlled infection (serum hepatitis B virus DNA by PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of hepatitis B virus DNA. Note: Patients with hepatitis C (positive hepatitis C virus antibody) who have controlled infection (undetectable hepatitis C virus RNA by PCR either spontaneously or in response to a successful prior course of anti-hepatitis C virus therapy) are permitted. - Have received a live vaccine within 30 days of study Day 1. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (eg, Flu-Mist®) are live attenuated vaccines, and are not allowed

Study Design


Intervention

Drug:
ANV419
ANV419 administered by intravenous (IV) infusion
Lenalidomide with low-dose dexamethasone
Lenalidomide and dexamethasone administered orally
Daratumumab
Daratumumab administered by subcutaneous injection

Locations

Country Name City State
Denmark Vejle Hospital Vejle
France Institut Paoli-Calmettes Marseille
France CHU de Nantes - Hôtel-Dieu Nantes
France Institut de cancérologie Strasbourg Europe (ICANS) Strasbourg
Germany Universitätsklinikum Jena Jena
Spain Hospital Clinic Barcelona Barcelona
Spain Hospital Universitario La Princesa Madrid
Spain Hospital General Universitario Morales Meseguer Murcia
Spain Hospital Clinico Universitario de Salamanca Salamanca
Switzerland Inselspital, Universitätsspital Bern Bern
Switzerland Kantonsspital St. Gallen Saint Gallen

Sponsors (1)

Lead Sponsor Collaborator
Anaveon AG

Countries where clinical trial is conducted

Denmark,  France,  Germany,  Spain,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) with ANV419 monotherapy Day 1 up to 12 months
Primary Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) with ANV419 in combination with lenalidomide plus low-dose dexamethasone Day 1 up to 12 months
Primary Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) with ANV419 in combination with daratumumab Day 1 up to 12 months
Secondary Serum concentration of ANV419 in blood Day 1 up to 12 months
Secondary Impact of ANV419 on the expression of markers of PBMC lineage in blood Day 1 up to 12 months
Secondary Levels of specific anti-ANV419 antibodies in blood Day 1 up to 12 months
Secondary Objective Response Rate (ORR) as defined by IMWG response criteria, with ANV419 monotherapy Day 1 up to 12 months
Secondary Objective Response Rate (ORR) as defined by IMWG response criteria, with ANV419 in combination with lenalidomide plus low-dose dexamethasone Day 1 up to 12 months
Secondary Objective Response Rate (ORR) as defined by IMWG response criteria, with ANV419 in combination with daratumumab Day 1 up to 12 months
Secondary Quality of life assessed with European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Day 1 up to 12 months
Secondary Quality of life assessed with European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Day 1 up to 12 months
Secondary Progression-free survival (PFS) according to IMWG response criteria Day 1 up to 12 months
Secondary Duration of Response (DOR) according to IMWG response criteria Day 1 up to 12 months
Secondary Clinical Benefit Rate (CBR) according to IMWG response criteria Day 1 up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1